Morgan Stanley Aridis Pharmaceuticals, Inc. Transaction History

Morgan Stanley

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.91 - $1.7 $1,160 - $2,167	-1,275 Closed	0 $0
Q1 2022 Oct 27, 2022	BUY	$1.33 - $2.59 $1,695 - $3,302	1,275 New	1,275 $2,000
Q1 2022 May 13, 2022	BUY	$1.33 - $2.59 $1,695 - $3,302	1,275 New	1,275 $2,000

50.2K

Ticker ARDS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,701,600
Description
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.